Home  »  Companies   »  Read This First Before You Buy Verve Therapeutics ...

Read This First Before You Buy Verve Therapeutics Inc. (NASDAQ: VERV) Stock

Verve Therapeutics Inc. (NASDAQ:VERV) shares, rose in value on Friday, 05/13/22, with the stock price up by 10.82% to the previous day’s close as strong demand from buyers drove the stock to $13.73.

Actively observing the price movement in the last trading, the stock closed the session at $12.39, falling within a range of $12.63 and $14.16. Referring to stock’s 52-week performance, its high was $78.00, and the low was $11.30. On the whole, VERV has fluctuated by -34.65% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.


As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.56, which is expected to increase to -$0.43 for fiscal year -$5.03 and then to about -$2.37 by fiscal year 2022.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that VERV’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

7 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 2 analyst(s), 5 recommend it as a Buy and 0 called the VERV stock Overweight. In the meantime, 0 analyst(s) believe the stock as Underweight and 0 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Overweight.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of VERV currently trading nearly -12.14% and -32.36% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 39.62, while the 7-day volatility ratio is showing 13.96% which for the 30-day chart, stands at 10.41%. Furthermore, Verve Therapeutics Inc. (VERV)’s average true range (ATR) is 1.62. The company’s stock has been forecasted to trade at an average price of $52.00 over the course of the next 52 weeks, with a low of $34.00 and a high of $75.00. Based on these price targets, the low is -147.63% off current price, whereas the price has to move -446.25% to reach the yearly target high. Additionally, analysts’ median price of $51.00 is likely to be welcomed by investors because it represents a decrease of -271.45% from the current levels.

In comparison, Johnson & Johnson (JNJ) has moved lower at -0.57% on the day and was up 3.89% over the past 12 months. On the other hand, the price of Pfizer Inc. (PFE) has fallen -0.93% on the day. The stock, however, is off 24.74% from where it was a year ago. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 2.39%. Meanwhile, the Dow Jones Industrial Improved by 1.47%.

Data on historical trading for Verve Therapeutics Inc. (NASDAQ:VERV) indicates that the trading volumes over the past 10 days have averaged 0.76 million and over the past 3 months, they’ve averaged 704.86K. According to company’s latest data on outstanding shares, there are 48.39 million shares outstanding.

Nearly 1.30% of Verve Therapeutics Inc.’s shares belong to company insiders and institutional investors own 71.80% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 7.62 million shares as on Feb 14, 2022, resulting in a short ratio of 11.05. According to the data, the short interest in Verve Therapeutics Inc. (VERV) stood at 15.81% of shares outstanding as of Feb 14, 2022; the number of short shares registered in Jan 13, 2022 reached 6.19 million. The stock has fallen by -62.76% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VERV stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts



Download Free eBook For


100% free. stop anytime no spam